<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management of chronic kidney disease | Management | Chronic kidney disease | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management of people with chronic kidney disease (CKD) or people at risk of CKD in primary care."/><meta data-react-helmet="true" property="og:description" content="Covers the management of people with chronic kidney disease (CKD) or people at risk of CKD in primary care."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/chronic-kidney-disease/management/management-of-chronic-kidney-disease/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management of chronic kidney disease | Management | Chronic kidney disease | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/chronic-kidney-disease/management/management-of-chronic-kidney-disease/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIG92ZXJmbG93PSJ2aXNpYmxlIiB2aWV3Qm94PSIwIDAgMjI2Ljc3IDExOS4wNiI+CiAgPHN0eWxlPgogICAgLnN0MHtmaWxsOiMyNzQ5NTF9CiAgPC9zdHlsZT4KICA8cGF0aCBkPSJNMTY4Ljk2IDIwLjk3Yy0zLjk0IDEuMjgtMy44NCAxLjI4IDUuOSAxLjg3IDUuNDEuMyAxMi40IDEuMjggMTUuNTQgMi4yN2w1LjYxIDEuODd2OC43OGMwIDEwLjA2IDEuMTggOS4zNy0xMC4zMyA2LjIxLTYuNTktMS43Ny0xOC4zLTIuMDctMjEuMjUtLjU5LTQuMzMgMi4zNy0uNjkgNi4yMSA2Ljk4IDcuNCA5LjM1IDEuNDggMTkuMTggNS4yMyAyMi4zMyA4LjU4IDQuNDMgNC43MyA1LjUxIDcuNDkgNS41MSAxMy42MSAwIDE0LjQtOS45NCAyMi4xOS0yOS44MSAyMy4zN2wtOS4zNS41OSA0LjQzIDIuMDdjMy42NCAxLjU4IDYuNDkgMS45NyAxNS43NCAyLjA3IDExLjAyIDAgMTEuNjEtLjEgMTguMi0zLjM1IDguNTItNC4xNCAxNS4zOS0xMS4wNiAxOS40OC0xOS42MiAyLjg1LTYuMDIgMy4xNS03LjQgMy4xNS0xNi40N3MtLjMtMTAuNDUtMy4xNS0xNi40N2MtNC4wMS04LjUzLTEwLjgyLTE1LjQyLTE5LjI4LTE5LjUyLTUuOS0yLjg2LTcuNzctMy4yNS0xNi4yMy0zLjU1LTUuOTktLjMtMTEuMDEuMDktMTMuNDcuODh6TTM0LjE4IDI0LjAzYy0xMC45MiAyLjc2LTE5Ljg3IDkuNjYtMjQuNjkgMTkuMDMtMi42NiA1LjMyLTIuODUgNi41MS0yLjg1IDE2LjU3IDAgOS44Ni4yIDExLjM0IDIuNjYgMTUuNzggNy4xOCAxMy41MSAyMi4xNCAyMC4yMSA0Mi4xMSAxOC44MyA0LjA2LS4yNiA4LjExLS43OSAxMi4xLTEuNThsMy42NC0xLjA4VjgyLjdjMC03Ljk5LS4yLTguODctMS42Ny04LjM4LTEwLjcyIDMuMjUtMjMuNDEgMy40NS0yOS40Mi41OS0yLjE3LTEuMS00LjExLTIuNi01LjcxLTQuNDQtMy45NC02LjAyLTMuOTQtMTcuNTUuMS0yMy4wNyAxLjgtMiAzLjkzLTMuNjcgNi4zLTQuOTMgMy42NC0yLjA3IDUuNTEtMi40NyAxMi4yLTIuMzcgNC4yNC4wNyA4LjQ2LjYgMTIuNTkgMS41OGw0LjcyIDEuNDgtLjMtOC45Ny0uMy05LjA3LTQuOTItMS4wOGMtNi40OS0xLjU5LTIwLjM2LTEuNDktMjYuNTYtLjAxek03Ni45OCA1OC42NHYzNS4wMWgyMC42NlY3MC40N2wxMS42MSAxMS42NCAxMS41MSAxMS41NGgyNy40NWwtMTcuMjItMTcuMjZjLTkuNDQtOS41Ny0xNy4yMi0xNy42NS0xNy40MS0xOC4xNC0uMi0uNDkgNi43OS04LjE4IDE1LjU0LTE3LjE2czE1Ljc0LTE2LjQ3IDE1Ljc0LTE2Ljg2LTUuOC0uNTktMTIuOTktLjU5aC0xMi45OWwtMTAuNjIgMTEuMDQtMTAuNTMgMTEuMTRWMzQuNjhsLS4xLTExLjA0SDc2Ljk4djM1eiIgY2xhc3M9InN0MCIvPgogIDxwYXRoIGQ9Ik0xMzkuNTQgNTIuMzNjLS44OSA0LjgzLS42OSAxMy4xMi40OSAxNi40Ny43OSAyLjI3IDIuMDcgMy40NSA1LjEyIDQuNTQgNy42NyAyLjc2IDEyIDMuNTUgMTkuODcgMy41NSA4LjY2IDAgMTIuNTktMS4zOCAxMy4wOC00LjU0LjM5LTIuNTYtMS45Ny0zLjU1LTE0LjI2LTYuMjEtNC4wNS0uODItOC4wNC0xLjk4LTExLjktMy40NS0zLjY0LTEuODctOC44NS03Ljc5LTkuNjQtMTAuOTUtLjc5LTMuMzYtMS45Ny0zLjA2LTIuNzYuNTl6TTcuNTggNDcuM3MtNC4zOSAxMi40Ny4xMyAyNC4zMSIgY2xhc3M9InN0MCIvPgogIDxwYXRoIGZpbGw9Im5vbmUiIGQ9Ik0wIDBoMjI2Ljc3djExOS4wNkgweiIvPgo8L3N2Zz4K" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Chronic kidney disease</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management of chronic kidney disease</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/chronic-kidney-disease/","name":"Chronic kidney disease"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/chronic-kidney-disease/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management of chronic kidney disease"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Chronic kidney disease: </span><span>Scenario: Management of chronic kidney disease</span></h1><p class="page-header__lead"><span>Last revised in May 2020</span></p></div><p class="visually-hidden">Covers the management of people with chronic kidney disease (CKD) or people at risk of CKD in primary care.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Chronic kidney disease chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management of chronic kidney disease"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management of chronic kidney disease</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: COVID-19"><a aria-current="false" href="../covid-19/index.html"><span class="stacked-nav__content-wrapper">Scenario: COVID-19</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#monitoring-disease-progression">Monitoring disease progression</a><ol aria-label="Sections within Monitoring disease progression" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-77e">Basis for recommendation</a></li></ol></li><li><a href="index.html#referral">Referral</a><ol aria-label="Sections within Referral" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-a5e">Basis for recommendation</a></li></ol></li><li><a href="index.html#management-in-primary-care">Management in primary care</a><ol aria-label="Sections within Management in primary care" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-9ae">Basis for recommendation</a></li></ol></li><li><a href="index.html#self-management-advice">Self-management advice</a><ol aria-label="Sections within Self-management advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-74d">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management-of-chronic-kidney-disease" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management-of-chronic-kidney-disease" class="visually-hidden">Scenario: Management of chronic kidney disease</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 79fdc5f7-249d-41df-a779-7e5ec63da360 --><!-- begin field 8ec04e04-c4f5-4807-a311-acbc015b46eb --><p>From age 18 years onwards.</p><!-- end field 8ec04e04-c4f5-4807-a311-acbc015b46eb --><!-- end item 79fdc5f7-249d-41df-a779-7e5ec63da360 --></div><section aria-labelledby="monitoring-disease-progression" class="ChapterBody-module--wrapper--2HCfk "><h3 id="monitoring-disease-progression">How should I monitor and identify disease progression?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2bea8cfe-c31f-4a39-b0a3-5e57435e1f12 --><!-- begin field 5c2b2473-3dcc-4832-8e6d-5a94bc1dacf6 --><p><strong>If a person has a <a class="topic-reference internal-reference" href="../../diagnosis/initial-investigations/index.html">confirmed diagnosis</a> of chronic kidney disease (CKD), arrange monitoring for disease progression and associated <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a>, and arrange specialist referral if appropriate.</strong></p><ul><li><strong>Identify any <a class="topic-reference internal-reference" href="../../background-information/causes/index.html">underlying causes</a> and risk factors for disease progression which will influence the frequency of monitoring.</strong></li><li><strong>Monitor renal function by checking serum creatinine and estimated glomerular filtration rate (eGFR) together with urinary albumin:creatinine ratio (ACR) to identify 'accelerated progression' of CKD.</strong><ul><li>This is indicated by a sustained decrease in eGFR of 25% or more from baseline <em>and</em> a change in <a class="topic-reference internal-reference" href="../../diagnosis/initial-investigations/index.html#classification-of-ckd">CKD category</a> within 12 months; <em>or</em> a sustained decrease in eGFR of 15 mL/min/1.73 m<sup>2 </sup>within 12 months.<ul><li>Be aware that small fluctuations in eGFR are common and do not necessarily indicate disease progression.</li></ul></li><li>To assess the rate of progression, repeat the serum eGFR three times over at least 3 months.<ul><li>If present, assess for any reversible <a class="topic-reference internal-reference" href="../../background-information/causes/index.html">cause</a> (such as potentially nephrotoxic drugs or volume depletion), arrange a renal tract ultrasound scan to identify an underlying structural cause, and arrange <a class="topic-reference internal-reference" href="index.html#referral">referral</a> to a nephrology specialist for further assessment and management.</li></ul></li><li>If the person has, or is at risk of, acute kidney injury (AKI):<ul><li>Consider stopping any potentially <a class="topic-reference internal-reference" href="../../background-information/causes/index.html">nephrotoxic drugs</a>. See the CKS topic on <a class="topic-reference external-reference" href="../../../acute-kidney-injury/index.html">Acute kidney injury</a> for more information on the urgent management of AKI.</li><li>Monitor for the development or progression of CKD for at least 2–3 years after an episode of AKI, even if serum creatinine has returned to baseline.</li></ul></li></ul></li><li><strong>Take into account the person's baseline eGFR and likely trajectory</strong> if the current rate of eGFR decline was to continue, to help decide on management and whether specialist referral is needed.<ul><li>Note previous trends of eGFR and ACR results, as the course of CKD is often non-linear. More frequent monitoring may be needed in people with previous variable or erratic renal function, and less frequent monitoring may be needed for those with stable results.<ul><li>For example, a rate of eGFR decline of 3 mL/min/1.73 m<sup>2 </sup>per year would be of greater concern in a person aged 40 years with a baseline eGFR of 30 mL/min/1.73 m<sup>2</sup>, than in a person aged 70 years with a baseline eGFR of 60 mL/min/1.73 m<sup>2</sup>.</li></ul></li><li>Table 1 provides a guide to recommended monitoring frequency.</li></ul></li></ul><p><strong>Table 1.</strong> Frequency of eGFR monitoring (number of times per year) for people with or at risk of CKD.</p><table><thead><tr><th colspan="2">Serum eGFR (mL/min/1.73 m<sup>2</sup>)</th><th colspan="3">Urinary ACR (mg/mmol)</th></tr></thead><tbody><tr><td colspan="2" rowspan="1"> </td><td colspan="1">A1 (< 3) Normal to mildly increased</td><td colspan="1">A2 (3–30) Moderately increased</td><td colspan="1">A3 (> 30) Severely increased</td></tr><tr><td colspan="2">G1 >=90 Normal and high</td><td colspan="1">=< 1</td><td colspan="1">1</td><td colspan="1">>= 1</td></tr><tr><td colspan="2">G2 60–89 Mild reduction related to normal range for a young adult</td><td colspan="1">=< 1</td><td colspan="1">1</td><td colspan="1">>= 1</td></tr><tr><td colspan="2">G3a 45–59 Mild to moderate reduction</td><td colspan="1">1</td><td colspan="1">1</td><td colspan="1">2</td></tr><tr><td colspan="2">G3b 30–44 Moderate to severe reduction</td><td colspan="1">=< 2</td><td colspan="1">2</td><td colspan="1">>= 2</td></tr><tr><td colspan="2">G4 15–29 Severe reduction</td><td colspan="1">2</td><td colspan="1">2</td><td colspan="1">3</td></tr><tr><td colspan="2">G5 <15 End-stage kidney failure</td><td colspan="1">4</td><td colspan="1">>=4</td><td colspan="1">>=4</td></tr><tr><td colspan="4"><strong>Data from:</strong> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>]</td><td colspan="1"> </td></tr></tbody></table><ul><li><p><strong>Arrange a full blood count (FBC) </strong>to exclude <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">renal anaemia</a> for people with <a class="topic-reference internal-reference" href="../../diagnosis/initial-investigations/index.html#classification-of-ckd">CKD category</a> stages 3b, 4, and 5, or if a person develops <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">symptoms</a> suggestive of anaemia.</p><ul><li>The frequency of subsequent monitoring depends on the FBC result and clinical judgement.</li><li>Consider checking FBC in people with CKD stages 1, 2, and 3a if anaemia is suspected clinically.</li><li>If anaemia is present, arrange tests to exclude other causes of anaemia, such as iron deficiency. See the CKS topic on <a class="topic-reference external-reference" href="../../../anaemia-iron-deficiency/index.html">Anaemia - iron deficiency</a> for more information.</li><li>If renal anaemia is suspected, arrange <a class="topic-reference internal-reference" href="index.html#referral">referral</a> to a nephrology specialist for further assessment and management.</li></ul></li><li><strong>Arrange serum calcium, phosphate, vitamin D, and parathyroid hormone tests </strong>to exclude <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">renal metabolic and bone disorder</a> for people with <a class="topic-reference internal-reference" href="../../diagnosis/initial-investigations/index.html#classification-of-ckd">CKD category</a> stages 4 or 5. The frequency of subsequent monitoring depends on the results and clinical judgement.<ul><li>Consider checking serum parathyroid hormone and vitamin D level in people with CKD stages 1, 2, 3a, and 3b if bone disease is suspected clinically, for example, if there is unexplained hypo- or hypercalcaemia.</li><li>See the CKS topics on <a class="topic-reference external-reference" href="../../../hypercalcaemia/index.html">Hypercalcaemia</a> and <a class="topic-reference external-reference" href="../../../vitamin-d-deficiency-in-adults-treatment-prevention/index.html">Vitamin D deficiency in adults - treatment and prevention</a> for more information.</li></ul></li></ul><!-- end field 5c2b2473-3dcc-4832-8e6d-5a94bc1dacf6 --><!-- end item 2bea8cfe-c31f-4a39-b0a3-5e57435e1f12 --></div><section aria-labelledby="basis-for-recommendation-77e" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-77e">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 77e9c3fe-47dd-4d08-8094-efdc2ae871c7 --><!-- begin field 7f63615d-c703-4e7d-90c8-bc34d9466a4b --><p>The recommendations on disease monitoring are largely based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>], <em>Acute kidney injury: prevention, detection and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013</a>], and <em>Chronic kidney disease: managing anaemia</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>]; the Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group publication <em>KDIGO Clinical practice guideline for anemia in chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012a</a>], the CKD Work Group publication <em>KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>], and the CKD-MBD Update Work Group <em>KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2017</a>]; and expert opinion in review articles on chronic kidney disease (CKD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Chawla, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Gaitonde, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</p><h5>Monitoring estimated glomerular filtration rate (eGFR) and urinary albumin:creatinine ratio (ACR) to identify disease progression</h5><ul><li>Early detection of disease progression can allow for timely preparation for renal replacement therapy, if indicated, for people with CKD stage 4 before progression to stage 5 disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">Gaitonde, 2017</a>].</li><li>People with a declining estimated glomerular filtration rate (eGFR) and progressive CKD have a worse prognosis, increased risk of complications, and require early intervention to prevent further renal deterioration compared with people with a stable eGFR. There is evidence that delayed referral leads to increased morbidity and mortality in people with advanced CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>]. The presence of proteinuria is associated with an increased risk of progression of CKD and death [<a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</li><li>The recommendations on frequency of eGFR monitoring are based on a review of 11 retrospective, cohort studies and the consensus opinion from the NICE guideline development group, which notes that, in addition, monitoring decisions should be tailored to the individual person [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>]. This is supported by the KDIGO CKD publication which recommends assessing GFR and albuminuria at least annually in people with CKD, and more often in people at higher risk of disease progression, and/or where measurement will impact on management decisions [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li></ul><h5>Identifying 'accelerated progression' of CKD</h5><ul><li>The NICE clinical guideline notes that people with accelerated progression of CKD are at increased risk of end-stage renal disease (ESRD) and other complications [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].</li><li>The definitions of accelerated progression of CKD are based on high-quality evidence from retrospective cohort studies and the experience and opinion of the NICE guideline development group [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].<ul><li>The NICE guideline development group based their definition of gradual CKD decline on biological and assay variability in serum creatinine concentrations and evidence from two cross-sectional studies, that a decline in eGFR of more than 2 mL/min/1.73 m<sup>2 </sup>per year is more than can be explained by ageing alone.</li><li>CKS notes that the KDIGO CKD publication also defines CKD progression, and the KDIGO definition of 'rapid progression' is different to that recommended by NICE ('more than 5mL/min/1.73m<sup>2</sup>/year' compared with 'a sustained decrease in eGFR of 15 mL/min/1.73 m<sup>2 </sup>within 12 months' defined by NICE) [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li></ul></li><li>The information that small fluctuations in eGFR are common and do not necessarily indicate progression are based on the KDIGO CKD publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>] and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</li><li>The recommendation to arrange a renal tract ultrasound for people with accelerated progression is based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and expert opinion in a review article, as long-standing intrinsic kidney disease may result in bilateral small kidneys; obstructive disease may cause hydronephrosis; enlarged cystic kidneys suggest polycystic kidney disease; and duplex investigations can assess blood flow and identify renal artery stenosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].<ul><li>CKS notes that the KDIGO CKD guideline recommends arranging a renal tract ultrasound in new presentations of CKD to determine the underlying cause, depending on clinical judgement, to assess kidney structure (shape, size, symmetry and evidence of obstruction) [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li></ul></li></ul><h5>Management and monitoring following acute kidney injury (AKI)</h5><ul><li>CKD is a risk factor for AKI. In turn, AKI is a risk factor for the development of CKD, the progression of existing CKD, an increased long-term risk of ESRD, cardiovascular disease, and excess mortality [<a class="bibliography-reference internal-reference" href="../../references/index.html">Chawla, 2014</a>].</li><li>The recommendation on the management of suspected or confirmed AKI is based on the NICE clinical guideline on AKI [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013</a>].<ul><li>The KDIGO CKD guideline advises to temporarily discontinue potentially nephrotoxic and renally excreted drugs in people with CKD and serious intercurrent illness to reduce the risk of AKI [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>]. This approach is supported by the expert opinion of previous external reviewers of this CKS topic.</li></ul></li><li>The recommendations on the need for prolonged monitoring for CKD following an episode of AKI are based on moderate-quality evidence from retrospective cohort studies in the NICE CKD guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].<ul><li>Evidence from 11 observational studies found an increased risk of new CKD or progression of pre-existing CKD in people with AKI. This increased risk persisted, even in people who made a complete recovery from the episode of AKI.</li></ul></li></ul><h5>Monitoring for renal anaemia</h5><ul><li>The recommendations on monitoring for anaemia are based on the NICE guidelines on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and anaemia in CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>], and the KDIGO Anemia Work Group publication, which recommends testing for anaemia at least annually in people with CKD stage 3 without anaemia, and more frequently for people with CKD stages 4–5 (who should be under specialist care) [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012a</a>].<ul><li>CKS notes that the KDIGO anaemia publication uses different thresholds for haemoglobin concentration to define renal anaemia compared with NICE (less than 13.0 g/dL [130 g/L] in males and 12.0 g/dL [120 g/L] in females, compared with less than 11 g/dL [110 g/L] defined by NICE) [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012a</a>].</li></ul></li></ul><h5>Monitoring for renal mineral and bone disorder</h5><ul><li>The recommendations on checking serum calcium, phosphate, vitamin D, and parathyroid hormone (PTH) are based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].<ul><li>Metabolic bone disease is often asymptomatic, with symptoms appearing only late in its course, so screening with blood tests can help to identify disease early. The KDIGO guideline on CKD notes that abnormalities of calcium and phosphate metabolism often occur later in the course of CKD than changes in vitamin D and parathyroid hormone (PTH), therefore it recommends checking these parameters early in the trajectory of CKD to assess the 'burden of illness' [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li><li>The NICE guideline development group reviewed five cross-sectional studies and one observational study. They concluded that although abnormal levels of calcium, phosphate, parathyroid hormone, and vitamin D were noted in some people with CKD stages 1, 2, or 3, the clinical significance of these levels was uncertain.</li></ul></li><li>CKS notes that the KDIGO mineral and bone disorder guideline recommends assessing for renal mineral and bone disease in people with CKD stage 3 and progressive disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2017</a>].</li></ul><!-- end field 7f63615d-c703-4e7d-90c8-bc34d9466a4b --><!-- end item 77e9c3fe-47dd-4d08-8094-efdc2ae871c7 --></div></section></section><section aria-labelledby="referral" class="ChapterBody-module--wrapper--2HCfk "><h3 id="referral">Who should I refer?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c89bf198-0d68-4ca3-8e74-8aca21fb1855 --><!-- begin field ec50cc5d-a845-4312-b328-9a8fb3582d3f --><ul><li><strong>Arrange an urgent 2-week wait referral</strong> if there is isolated <a class="topic-reference internal-reference" href="../../diagnosis/diagnosis/index.html">persistent haematuria</a> and a urological cancer is suspected. See the CKS topic <a class="topic-reference external-reference" href="../../../urological-cancers-recognition-referral/index.html">Urological cancers - recognition and referral</a> for more information.</li><li><strong>Arrange referral to a nephrology specialist, the urgency depending on clinical judgement, if there is:</strong><ul><li>An estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m<sup>2</sup>.<ul><li><a class="topic-reference internal-reference" href="index.html#monitoring-disease-progression">Disease monitoring</a> may take place in primary care as part of a shared care agreement.</li></ul></li><li>Accelerated progression of chronic kidney disease (CKD), defined as:<ul><li>A sustained decrease in eGFR of 25% or more within 12 months <em>and </em>a change in <a class="topic-reference internal-reference" href="../../diagnosis/initial-investigations/index.html#classification-of-ckd">CKD category</a>.</li><li>A sustained decrease in eGFR of 15 mL/min/1.73 m<sup>2 </sup>or more within 12 months.</li></ul></li><li>A urinary albumin:creatinine ratio (ACR) of 70 mg/mmol or more, unless proteinuria is known to be associated with diabetes mellitus and is managed appropriately. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-1/index.html">Diabetes - type 1</a> for more information.</li><li>A urinary ACR of 30 mg/mmol or more together with <a class="topic-reference internal-reference" href="../../diagnosis/diagnosis/index.html">persistent haematuria</a>, after exclusion of a urinary tract infection (UTI). See the CKS topics on <a class="topic-reference external-reference" href="../../../urinary-tract-infection-lower-men/index.html">Urinary tract infection (lower) - men</a> and <a class="topic-reference external-reference" href="../../../urinary-tract-infection-lower-women/index.html">Urinary tract infection (lower) - women</a> for more information.</li><li>Hypertension that remains uncontrolled despite the use of at least four antihypertensive drugs at therapeutic doses. See the CKS topic on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for more information.</li><li>A suspected or confirmed rare or <a class="topic-reference internal-reference" href="../../background-information/causes/index.html">genetic cause</a> of CKD, such as polycystic kidney disease.</li><li>Suspected renal artery stenosis.<ul><li>This should be suspected if there is a greater than 25% reduction in eGFR within 3 months of starting (or increasing the dose of) a renin-angiotensin system antagonist, refractory hypertension, pulmonary oedema, and/or a renal artery bruit.</li></ul></li><li>A suspected <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complication</a> of CKD. Specialist management of:<ul><li>A decline in nutritional status or malnutrition, and persistent hyperkalaemia, may include specialist dietary advice about potassium, phosphate, calorie and salt intake; and end-stage renal disease (ESRD) may require renal replacement therapy (haemodialysis/peritoneal dialysis or eventual kidney transplantation).</li><li>Renal anaemia may include treatment with erythropoiesis-stimulating agents, and possible intravenous iron if there is associated refractory iron deficiency.</li><li>Renal mineral and bone disorder may involve phosphate dietary restriction, use of phosphate binders, and specialist endocrinology input.</li><li>Persistent metabolic acidosis may involve oral bicarbonate supplementation.</li></ul></li></ul></li><li><strong>Arrange referral to a urology specialist, the urgency depending on clinical judgement, if there is:</strong><ul><li>Suspected urinary tract obstruction (for example the bladder is palpable or hydronephrosis is seen on renal tract ultrasound).</li><li>Note: emergency admission may be required if the person is in urinary retention; has severe hyperkalaemia (potassium greater than 6 mmol/L); severe uraemia; or signs of fluid overload or dehydration.</li></ul></li></ul><!-- end field ec50cc5d-a845-4312-b328-9a8fb3582d3f --><!-- end item c89bf198-0d68-4ca3-8e74-8aca21fb1855 --></div><section aria-labelledby="basis-for-recommendation-a5e" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-a5e">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a5e80127-0bd0-4c9c-8c93-c99a2b126920 --><!-- begin field 56d695c4-2190-47df-9ec7-92ab112663df --><p>The recommendations on referral are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>], <em>Chronic kidney disease: managing anaemia</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>], and <em>Suspected cancer: recognition and referral</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2017b</a>]; the Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group publication <em>KDIGO Clinical practice guideline for anemia in chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012a</a>], the CKD Work Group publication <em>KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>], and the CKD-MBD Update Work Group <em>KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2017</a>]; a cohort study on the impact of haematuria on CKD prognosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Orlandi, 2018</a>], and expert opinion in review articles on chronic kidney disease (CKD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bello, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Gaitonde, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</p><h5>Arranging an urgent 2-week wait referral</h5><ul><li>The recommendation to arrange an urgent referral if urological cancer is suspected is based on the NICE clinical guideline on suspected cancer [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2017b</a>].</li></ul><h5>Arranging referral to a nephrology specialist</h5><ul><li>The recommendations on nephrology referral criteria are largely based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].<ul><li>NICE reviewed the literature and did not find any good-quality evidence to guide referral recommendations, and these were therefore based on the experience and opinion of the NICE guideline development group.</li><li>It noted a key aim is to avoid the late referral of people with CKD likely to progress to need renal replacement therapy within one year.</li></ul></li><li>This approach is supported by the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>]. In addition, expert opinion in review articles notes that timely referral of people with CKD stages 4 or 5 allows for planning for end-stage renal disease (ESRD) and preparation for possible renal replacement therapy, with potentially improved outcomes and survival rates [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Gaitonde, 2017</a>].<ul><li>The recommendation to refer people with significant proteinuria is based on the fact that this may require specialist management and may be secondary to an underlying cause such as myeloma [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li><li>The recommendation to refer people with proteinuria and haematuria after exclusion of a urinary tract infection (UTI) is based on the fact that renal biopsy or specialist imaging may be needed to identify the underlying cause of CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>]. This is in line with the KDIGO guideline on CKD which recommends referral for people with CKD and unexplained, persistent haematuria [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>]. In addition, a cohort study of adults with CKD found the presence of haematuria (one positive urine dipstick test) was associated with a higher risk of progressive disease, ESRD, and mortality during the first two years of follow-up [<a class="bibliography-reference internal-reference" href="../../references/index.html">Orlandi, 2018</a>].</li><li>The information on when to suspect renal artery stenosis is based on expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Gaitonde, 2017</a>].</li></ul></li><li>The information on the specialist management of complications of CKD is based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>], three KDIGO guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2017</a>], and expert opinion in various review articles.<ul><li>The recommendations on the management of ESRD and malnutrition are largely based on the NICE clinical guideline on CKD and the KDIGO guideline on CKD, which note that specialist dietitian input on salt, phosphate, potassium, and protein intake may be needed, tailored to the severity of CKD. This approach is supported by expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Gaitonde, 2017</a>].</li><li>The recommendations on the treatment options for renal anaemia are based on the fact that erythropoietin stimulates red blood cell production in the bone marrow and drives haemoglobin homeostasis. Treatment with erythropoiesis-stimulating agents may be offered, but treatment response may be limited by co-existent iron deficiency, which may require management with oral or intravenous iron therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bello, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</li><li>The recommendations on the management of renal mineral and bone disorder are based on the KDIGO mineral and bone disorder guideline, which notes the role of specialist phosphate-lowering treatment and limiting dietary phosphate intake. This is supported by expert opinion in review articles which recommend referring people with CKD if there is hyperphosphataemia or secondary hyperparathyroidism [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</li><li>The recommendations on the management of persistent metabolic acidosis is based on the NICE clinical guideline on CKD, the KDIGO guideline on CKD, and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>].</li></ul></li></ul><h5>Arranging referral to a urology specialist</h5><ul><li>The recommendations on urology referral criteria are largely based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].</li><li>The recommendations on emergency admission are based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>]. They are also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field 56d695c4-2190-47df-9ec7-92ab112663df --><!-- end item a5e80127-0bd0-4c9c-8c93-c99a2b126920 --></div></section></section><section aria-labelledby="management-in-primary-care" class="ChapterBody-module--wrapper--2HCfk "><h3 id="management-in-primary-care">How should I manage a person in primary care?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 33a839cf-7d37-42ee-8560-c12bac23f63d --><!-- begin field e3223085-3c26-4615-9a0e-9a4dab36420f --><p><strong>If a person has a <a class="topic-reference internal-reference" href="../../diagnosis/initial-investigations/index.html">confirmed</a> diagnosis of chronic kidney disease (CKD), arrange regular follow-up in primary care, the frequency depending on clinical judgement.</strong></p><ul><li><strong>Assess for and manage risk factors and co-morbidities of CKD, including:</strong><ul><li>Underlying <a class="topic-reference internal-reference" href="../../background-information/causes/index.html">causes</a>  of CKD and risk factors for disease progression (including potentially reversible causes), and manage appropriately.</li><li>Any potentially <a class="topic-reference internal-reference" href="../../background-information/causes/index.html">nephrotoxic drugs</a> that may cause acute kidney injury (AKI) in severe intercurrent illness, and reduce or stop as appropriate. See the CKS topic on <a class="topic-reference external-reference" href="../../../acute-kidney-injury/index.html">Acute kidney injury</a> for more information.</li><li>Monitoring for <a class="topic-reference internal-reference" href="index.html#monitoring-disease-progression">disease progression</a>, the frequency depending on the person's stage of CKD, risk factors for progression, and clinical judgement.</li><li><a class="topic-reference internal-reference" href="index.html#self-management-advice">Lifestyle risk factors</a> for disease progression, and manage appropriately.</li><li>Any associated anxiety or depression. See the CKS topics on <a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a> and <a class="topic-reference external-reference" href="../../../depression/index.html">Depression</a> for more information.</li><li>Risk of cardiovascular disease (CVD) and manage appropriately.<ul><li>Note: do not use a risk assessment tool to assess CVD risk in people with CKD. See the CKS topic on <a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a> for more information.</li></ul></li></ul></li><li><strong>Assess for hypertension. If a person is not diabetic and has:</strong><ul><li>A urinary albumin:creatinine ratio (ACR) of less than 30 mg/mmol and associated hypertension, arrange appropriate management. See the CKS topic on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for more information.</li><li>A urinary ACR of 30 mg/mmol or more and associated hypertension, prescribe a low-cost renin-angiotensin system antagonist (such as lisinopril or losartan) to achieve the optimal tolerated dose, depending on contraindications, cautions, and drug interactions.<ul><li>Do not prescribe a combination of renin-angiotensin system antagonists to people with CKD, such as lisinopril <em>and </em>losartan.</li><li>See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/ace-inhibitors-aiiras/index.html">ACE-inhibitors and AIIRAs</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information.</li></ul></li><li>A urinary ACR of less than 70 mg/mmol, aim for a blood pressure target of:<ul><li>Systolic less than 140 mmHg (target range 120–139 mmHg) and diastolic less than 90 mmHg.</li></ul></li><li>A urinary ACR of 70 mg/mmol or more, aim for a blood pressure target of:<ul><li>Systolic less than 130 mmHg (target range 120–129 mmHg) and diastolic less than 80 mmHg.</li></ul></li><li>Hypertension which remains uncontrolled despite the use of at least four antihypertensive drugs at therapeutic doses, arrange <a class="topic-reference internal-reference" href="index.html#referral">referral</a> to a nephrology specialist.</li></ul></li><li><strong>If a person has a urinary ACR of 70 mg/mmol or more (irrespective of blood pressure or cardiovascular disease):</strong><ul><li>Prescribe a low-cost renin-angiotensin system antagonist (for example lisinopril or losartan) to achieve the optimal tolerated dose, depending on contraindications, cautions, and drug interactions, <em>and</em></li><li>Arrange referral to a nephrology specialist unless proteinuria is known to be associated with diabetes mellitus and is managed appropriately. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-1/index.html">Diabetes - type 1</a> for more information.<ul><li>Do not prescribe a combination of renin-angiotensin system antagonists to people with CKD, such as lisinopril <em>and </em>losartan.</li><li>See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/ace-inhibitors-aiiras/index.html">ACE-inhibitors and AIIRAs</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information.</li></ul></li></ul></li><li><strong>If a person has diabetes mellitus:</strong><ul><li>Aim for a blood pressure target of systolic less than 130 mmHg (target range 120–129 mmHg) and diastolic less than 80 mmHg.</li><li>With a urinary ACR of 3 mg/mmol or more, prescribe a low-cost renin-angiotensin system antagonist (for example lisinopril or losartan) to achieve the optimal tolerated dose, depending on contraindications, cautions, and drug interactions.<ul><li>Do not prescribe a combination of renin-angiotensin system antagonists to people with CKD, such as lisinopril <em>and </em>losartan.</li><li>See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/ace-inhibitors-aiiras/index.html">ACE-inhibitors and AIIRAs</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information.</li></ul></li><li>Aim to optimize blood glucose control as much as possible. See the CKS topics on <a class="topic-reference external-reference" href="../../../diabetes-type-1/index.html">Diabetes - type 1</a> and <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information.</li></ul></li><li><strong>For all people with CKD, prescribe lipid-lowering therapy with a statin, </strong>for the primary or secondary prevention of CVD.<ul><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for more information on cautions and contraindications of statins, starting and titrating treatment, and treatment targets.</li><li>Be aware that renal impairment is a risk factor for myopathy and rhabdomyolysis adverse effects of statins. For people who have an eGFR of 30 mL/min/1.73 m<sup>2 </sup>or less, consider seeking specialist advice before increasing statin doses.</li></ul></li><li><strong>Prescribe an antiplatelet drug for the secondary prevention of CVD.</strong><ul><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../antiplatelet-treatment/index.html">Antiplatelet treatment</a> for more prescribing information, including drug cautions and contraindications.</li></ul></li><li><strong>Ensure the person is offered immunizations</strong> for influenza and pneumococcal disease to reduce infection risk, if appropriate. See the CKS topics on <a class="topic-reference external-reference" href="../../../immunizations-seasonal-influenza/index.html">Immunizations - seasonal influenza</a> and <a class="topic-reference external-reference" href="../../../immunizations-pneumococcal/index.html">Immunizations - pneumococcal</a> for more information.</li></ul><!-- end field e3223085-3c26-4615-9a0e-9a4dab36420f --><!-- end item 33a839cf-7d37-42ee-8560-c12bac23f63d --></div><section aria-labelledby="basis-for-recommendation-9ae" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-9ae">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9ae7ed55-7c11-43d6-96ac-1ca22af3e7a0 --><!-- begin field 5d9b7603-75f6-48e5-8377-21b7815cf564 --><p>The recommendations on management in primary care are largely based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and <em>Cardiovascular disease: risk assessment and reduction, including lipid modification</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016</a>]; the Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group publication <em>KDIGO Clinical practice guideline for the management of blood pressure in chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012b</a>] and the CKD Work Group publication <em>KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>]; a longitudinal study of chronic kidney disease (CKD) prevalence [<a class="bibliography-reference internal-reference" href="../../references/index.html">Jameson, 2014</a>], and expert opinion in review articles on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</p><h5>Assessing and managing risk factors</h5><ul><li>The recommendations on assessing for and managing risk factors and co-morbidities are largely based on the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>] and the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].<ul><li>Assessment for an underlying cause or risk factor for CKD may allow potentially reversible factors to be modified or treated, reducing the risk of cardiovascular disease (CVD) and disease progression. In addition, identification of an underlying cause may determine the disease treatment options available [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li></ul></li><li>Expert opinion in review articles also highlights the importance of good medicines management to reduce the risk of CKD progression and acute kidney injury (AKI) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>].</li><li>The recommendation to manage lifestyle risk factors is largely based on the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>] and the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].</li><li>The recommendation on identifying and managing any co-morbid anxiety or depression is based on the fact that a diagnosis of CKD may cause significant anxiety and negatively affect a person's quality of life [<a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</li><li>The recommendation not to use a risk assessment tool to assess cardiovascular risk is based on the NICE clinical guideline on cardiovascular risk assessment [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016</a>].<ul><li>The NICE guideline development group found no evidence relating to risk assessment tools specific for people with CKD, and judged people with CKD to be at an already high risk of developing CVD.</li></ul></li></ul><h5>Management of hypertension</h5><ul><li>A reduction in blood pressure in people with CKD has the potential dual benefits of reducing risk of disease progression and reducing cardiovascular risk [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>]. Expert opinion in a review article notes that prevention of CKD disease progression includes management of hypertension, appropriate use of renin-angiotensin system antagonists, and avoidance of nephrotoxic drugs where possible [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>]. This approach is supported by expert opinion in a retrospective study of CKD prevalence, which notes that disease progression may be delayed or prevented by the management of cardiovascular risk factors [<a class="bibliography-reference internal-reference" href="../../references/index.html">Jameson, 2014</a>].<ul><li>The NICE clinical guideline found no evidence that renin-angiotensin system antagonists are more beneficial than other antihypertensive drugs for the same level of blood pressure reduction, in people with a urinary albumin:creatinine ratio (ACR) of less than 30 mg/mmol.</li></ul></li><li>The recommendations on the thresholds for proteinuria that require treatment with a renin-angiotensin system antagonist are largely based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].<ul><li>The NICE guideline development group noted that the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor antagonists (AIIRAs) appeared to be more closely related to the presence or absence of proteinuria rather than blood pressure control.</li><li>This approach is supported by expert opinion in a review article which notes that greater early reductions in proteinuria are associated with slower progression of kidney disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>]. </li></ul></li><li>The recommendation to use a renin-angiotensin system antagonist first-line to treat hypertension in people with CKD and a urinary ACR of 30 mg/mmol or more is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and the KDIGO Blood Pressure Work Group publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012b</a>].<ul><li>The NICE guideline development group based their recommendations on high- to very low-quality randomized controlled trial (RCT) evidence and cost-effectiveness data.</li><li>The NICE guideline development group and KDIGO Work Group did not specify whether to prescribe an ACE-inhibitor or AIIRA first-line, as they did not find any evidence to suggest an advantage of one drug class over another.</li><li>The recommendation to avoid prescribing combined ACE-inhibitor <em>and</em> AIIRA therapy in people with CKD is based on moderate- to very low-quality RCT evidence in the NICE clinical guideline which showed insufficient evidence of benefit of combined therapy over the maximum recommended dose of each individual drug. This approach is supported in the KDIGO guideline on CKD which found insufficient evidence to recommend dual therapy to prevent progression of CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li><li>A Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update also recommends avoiding the combined use of renin-angiotensin system antagonists, and notes the increased risk of hyperkalaemia, hypotension, and worsening renal function compared with either class of drug alone [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2014a</a>]. This is supported by expert opinion in a review article which notes an increased risk of complications such as AKI and severe hyperkalaemia, and no evidence of reducing cardiovascular or mortality risk compared with single agent therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>].</li></ul></li><li>The recommendations on the blood pressure treatment targets in people with CKD are largely based on the NICE clinical guideline on CKD which found evidence that there are optimal blood pressure ranges, with increased risk of adverse outcomes both above and below the optimal range [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].<ul><li>A systolic blood pressure — less than 120 mmHg is associated with an increase in all-cause mortality, cardiovascular mortality, stroke, and heart failure; more than 140 mmHg is associated with increased risk of end-stage renal disease (ESRD), doubling of serum creatinine concentration, and death.</li><li>A diastolic blood pressure — less than 60 mmHg is associated with an increased risk of death, myocardial infarction, and decline in estimated glomerular filtration rate (eGFR); more than 80 mmHg is associated with an increased risk of ESRD, doubling of serum creatinine concentration, and death. The guideline development group noted that when treatment is given to maintain systolic blood pressure in the optimal range, this can result in diastolic blood pressure falling below its optimal range, therefore it specified a target diastolic blood pressure rather than optimal range.</li><li>The GDG noted that adverse outcomes seen with lower blood pressure may have been subject to reverse causality (the adverse outcome resulted in the low blood pressure reading rather than vice versa).</li><li>CKS notes the differences in blood pressure targets and cut-offs in proteinuria thresholds between the NICE clinical guideline and the KDIGO Blood Pressure Work Group publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012b</a>].</li></ul></li></ul><h5>Management of diabetes mellitus</h5><ul><li>The recommendations on blood pressure treatment targets and threshold for proteinuria that requires treatment with a renin-angiotensin system antagonist are based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li><li>The recommendation on the importance of optimizing blood glucose control is based on the fact this can prevent or delay progression of the microvascular complications of diabetes mellitus including diabetic kidney disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>]. This is supported by expert opinion in a longitudinal study and a review article which note that optimal management of diabetes and good blood glucose control reduces the risk of CKD disease progression [<a class="bibliography-reference internal-reference" href="../../references/index.html">Jameson, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>].</li></ul><h5>Prescribing lipid-lowering therapy</h5><ul><li>The recommendations on offering lipid-lowering therapy are based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>], the NICE clinical guideline on cardiovascular risk assessment and lipid modification [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016</a>], and the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].<ul><li>People with CKD are at increased risk of CVD and will benefit from CVD risk modification including the use of lipid-modifying therapy. The NICE guideline development group noted the trial evidence on statin use in CVD has largely excluded people with CKD. It found no evidence to assume that the effectiveness of lipid-modifying therapy would be different for people with CKD compared with the general population [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].</li></ul></li><li>The recommendation to seek specialist advice before increasing the statin dose in people with an eGFR of 30 mL/min/1.73 m<sup>2 </sup>or less is based on the expertise and opinion of the NICE guideline development group, which noted that people with this level of CKD have an increased risk of muscle adverse effects as a result of taking high-dose statins [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016</a>].</li></ul><h5>Prescribing antiplatelet therapy</h5><ul><li>The recommendation to offer antiplatelet therapy is based on observational studies and the experience and opinion of the NICE guideline development group [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>]. This approach is in line with the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li></ul><h5>Offering influenza and pneumococcal immunizations</h5><ul><li>The recommendation to ensure that appropriate immunizations are offered is based on the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>] and is supported by expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>].</li></ul><!-- end field 5d9b7603-75f6-48e5-8377-21b7815cf564 --><!-- end item 9ae7ed55-7c11-43d6-96ac-1ca22af3e7a0 --></div></section></section><section aria-labelledby="self-management-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="self-management-advice">What self-management advice should I give?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item bbb25153-dbdc-475f-92df-fe6dbea2a6b7 --><!-- begin field b1fc6d81-77eb-4046-85ec-b00f8b97a648 --><p><strong>If a person has a <a class="topic-reference internal-reference" href="../../diagnosis/initial-investigations/index.html">confirmed</a> diagnosis of chronic kidney disease (CKD), offer self-management advice in relation to the underlying <a class="topic-reference internal-reference" href="../../background-information/causes/index.html">cause</a>, <a class="topic-reference internal-reference" href="../../diagnosis/initial-investigations/index.html#classification-of-ckd">disease severity</a>, associated <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a>, and <a class="topic-reference internal-reference" href="index.html#monitoring-disease-progression">risk of progression</a>.</strong></p><ul><li><strong>Provide sources of information, advice, and support</strong>, such as:<ul><li>Kidney Care UK (website available at <a data-hyperlink-id="7ac85e2d-8697-440d-baee-a9f201669639" href="https://www.kidneycareuk.org/" target="_blank">www.kidneycareuk.org</a>) which is a national kidney charity which has a telephone support helpline (telephone 01420 541424) and several <a data-hyperlink-id="c6ee08d5-c950-4231-aec9-a9f201669656" href="https://www.kidneycareuk.org/about-kidney-health/order-or-download-booklets/" target="_blank">leaflets</a> on CKD and associated conditions.</li><li>The NHS patient information leaflet <a data-hyperlink-id="18f0dbb3-ab77-43b1-ac37-a9f2016696c4" href="https://www.nhs.uk/conditions/kidney-disease/" target="_blank">Chronic kidney disease</a>.</li><li>The patient information leaflet <a data-hyperlink-id="7977cd85-629e-4bcb-8fb0-a9f2016696d8" href="https://patient.info/health/chronic-kidney-disease-leaflet" target="_blank">Chronic kidney disease</a> available on the <a data-hyperlink-id="cf267cb4-a73a-482f-9119-a9d0014a9cf2" href="https://patient.info/">www.patient.info</a> website.</li></ul></li><li><strong>Advise on healthy lifestyle measures, such as:</strong><ul><li>Stopping smoking if appropriate. See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for more information.</li><li>Drinking alcohol in moderation. See the CKS topic on <a class="topic-reference external-reference" href="../../../alcohol-problem-drinking/index.html">Alcohol - problem drinking</a> for more information.</li><li>Maintaining a healthy body weight. See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li><li>Eating a healthy diet and taking regular exercise.<ul><li>A low-protein diet (dietary protein intake of less than 0.6–0.8/kg/day) is not routinely recommended.</li><li>Specialist dietary advice about potassium, phosphate, calorie, and salt intake may be arranged by the person's specialist for people with end-stage CKD following <a class="topic-reference internal-reference" href="index.html#referral">referral</a>.</li></ul></li></ul></li><li><strong>Advise the person to avoid the use of over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) where possible</strong> and avoid herbal remedies, and use protein supplements with caution. See the CKS topic on <a class="topic-reference external-reference" href="../../../nsaids-prescribing-issues/index.html">NSAIDs - prescribing issues</a> for more information.</li><li><strong>Advise on the increased risk of acute kidney injury (AKI) </strong>if there is severe, intercurrent illness. See the CKS topic on <a class="topic-reference external-reference" href="../../../acute-kidney-injury/index.html">Acute kidney injury</a> for more information on diagnosis and management.</li></ul><!-- end field b1fc6d81-77eb-4046-85ec-b00f8b97a648 --><!-- end item bbb25153-dbdc-475f-92df-fe6dbea2a6b7 --></div><section aria-labelledby="basis-for-recommendation-74d" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-74d">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 74d7bf24-9c44-43de-98fc-eb2a5e616d0d --><!-- begin field 82062509-4490-4656-a722-8157441470e0 --><p>The recommendations on self-management advice are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>]; the Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group publication <em>KDIGO Clinical practice guideline for the management of blood pressure in chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2012b</a>] and the CKD Work Group publication <em>KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>]; and expert opinion in review articles on chronic kidney disease (CKD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bello, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</p><h5>Providing sources of information and support</h5><ul><li>The NICE clinical guideline notes that patient education is important to allow people to understand their condition and make informed decisions about management [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].</li></ul><h5>Advice on healthy lifestyle measures</h5><ul><li>The recommendations on lifestyle modification are largely based on a NICE evidence review of small observational studies and the experience and opinion of the NICE guideline development group [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>], together with recommendations in the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>] and expert opinion in review articles.<ul><li>Smoking has been associated with more severe proteinuria and progression of CKD, and obesity leads to CKD through the development of diabetes mellitus and hypertension risk factors [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].</li><li>NICE found no specific evidence that weight control, healthy eating, taking regular exercise and not smoking had additional benefits in people with CKD, however it concluded that management of cardiovascular risk factors is beneficial to reduce the risk of cardiovascular complications and CKD progression [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>]. This approach is supported by expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Webster, 2017</a>].</li></ul></li><li>The information that low-protein diets are not routinely recommended is based on the NICE clinical guideline which found very-low to high-quality evidence that the use of low-protein diets for all people with CKD did not reduce the risk of disease progression [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>]. The KDIGO CKD guideline review of the evidence notes that the role of dietary protein restriction in slowing progression of CKD is controversial, and found no convincing or conclusive evidence that long-term protein restriction delayed the progression of CKD. It did, however, support a reduction in dietary protein in selected people with CKD stages 4–5 [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li><li>The information about specialist diets for people with end-stage renal disease (ESRD) is based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>], the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>], and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bello, 2017</a>].<ul><li>The NICE guideline notes that people with ESRD may have nausea and a loss of appetite due to uraemia, and may benefit from specialist dietary advice to reduce the risk of malnutrition and increased infection rates.</li><li>CKS notes that the KDIGO guideline recommends lowering salt intake to less than 2g/day for people with CKD, unless contraindicated, which differs from the approach recommended in the NICE guideline. Low dietary salt intake can improve blood pressure control, reduce proteinuria, and reduce the risk of CKD progression [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fraser, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bello, 2017</a>].</li></ul></li></ul><h5>Advice on over-the-counter medication</h5><ul><li>The recommendation to avoid nonsteroidal anti-inflammatory drugs (NSAIDs) where possible is based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>].<ul><li>Short-term use of NSAIDs can lead to a sudden decrease in glomerular filtration rate (GFR), and long-term use, even at therapeutic doses, can be associated with disease progression. The guideline development group recommended that if NSAIDs are considered necessary, their effect on GFR should be monitored, and they should be stopped if there is evidence of disease progression.</li></ul></li><li>The recommendation to avoid herbal remedies and use protein supplements with caution is based on the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>].</li></ul><h5>Advice on risk of acute kidney injury (AKI)</h5><ul><li>The recommendation on advising people with CKD on the risks of AKI is based on the NICE clinical guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and the KDIGO guideline on CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">KDIGO, 2013</a>]. It is supported by expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Vassalotti, 2016</a>].</li></ul><!-- end field 82062509-4490-4656-a722-8157441470e0 --><!-- end item 74d7bf24-9c44-43de-98fc-eb2a5e616d0d --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/chronic-kidney-disease/management/management-of-chronic-kidney-disease/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>